bluebird bio (BLUE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BLUE bluebird bio

Watchlist

0.449
-0.006-1.36%

Close Dec 9 16:00 ET

0.503
+0.054+11.98%

Pre 04:27 ET

87.31MMarket Cap-249P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
BenzingaDec 9 02:48 ET
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
BenzingaDec 7 15:30 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
BenzingaDec 5 16:05 ET
Trending Stocks Today | PainReform Surges 67.16% Post-Market
Moomoo NewsDec 4 16:25 ET
Express News | Bluebird bio Announces 1-for-20 Reverse Stock Split
ReutersDec 4 16:05 ET
Bluebird Bio Announces 1-for-20 Reverse Stock Split
BusinesswireDec 4 16:05 ET

Comments

Bull X Bear

18 hours ago

3 Companies to lookout for

$Quantum-Si (QSI.US)$ Quantum-Si is a pioneering company in the field of protein sequencing and analysis, with a focus on applying semiconductor technology to advance life sciences. Here’s a comprehensive overview of what Quantum-Si does, its technology, and its significance:
Company Overview
• Founded: 2013
• Founder: Dr. Jonathan Rothberg, a serial entrepreneur also known for inventing next-generation DNA sequencing (NGS).
• Headquarters: Guilford, Connecticut, USA
• ...

104659513

Yesterday 18:03

$bluebird bio (BLUE.US)$ let go bird 🚀

Jaguar8

Yesterday 09:40

Currently 0.5370 on overnight trading.

$bluebird bio (BLUE.US)$

This_Guy

Yesterday 07:19

$bluebird bio (BLUE.US)$
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Positive
94.7% of evaluable patients achieved complete resolution of severe VOEs
86.8% of evaluable patients achieved complete resolution of VOEs
100% success rate in pediatric patients (10/10) for VOE resolution
No stroke recurrence in patients with prior history through 9 y...

Trytosaveabit

Yesterday 05:43

Watching! PR/update released Saturday

$bluebird bio (BLUE.US)$ Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or Near-Normal Adult Hb Levels At ASH Meeting
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...

Heat List

Overall

No Data